SecBot SecBot
Biotech Drug Report Generated Nov 9, 2026

SGX302

SNGX·Soligenix, Inc.
BEARISH
Drug Impact Rating3/10
Trial phase
Phase 2a (completed)
Time to market
At least 3-5 years if development resumes; SGX302 has only completed a small Phase 2a trial (15 patients) and would need Phase 2b and Phase 3 trials before any regulatory submission. The company's strategic review and limited cash make the timeline highly uncertain.
Why 3/10
SGX302 has no scheduled hard binary catalyst (no PDUFA, no Phase 3 readout) in the next ~12 months. The Phase 2a trial is complete, and the company is exploring strategic alternatives after its lead CTCL program failed. ImpactScore is 3 because this is an early-stage program at a distressed company with no near-term catalyst.
Actionable Insight BEARISH

SGX302 has no upcoming binary catalyst; the Phase 2a is complete and the company is exploring strategic alternatives after its lead CTCL program failed. Watch for a partnership or licensing deal for SGX302, or a broader M&A outcome for Soligenix itself. The Q3 2026 earnings press release (Nov 6) is the most recent update and noted the company is evaluating strategic alternatives.

Price Chart

Loading chart...

Executive Summary

SGX302 is Soligenix's topical synthetic hypericin gel in development for mild-to-moderate psoriasis, using photodynamic therapy (visible light activation). A Phase 2a trial completed with positive signals: in the final cohort (Dec 2025), 3 of 4 patients achieved PASI 75 with good tolerability. However, SGX302 is an early-stage program at a company in distress. Soligenix's lead asset HyBryte (SGX301, same active ingredient) failed its pivotal Phase 3 FLASH2 trial in April 2026, halted for futility. The company has ~$9M cash, no revenue, and is exploring strategic alternatives including partnerships or a sale. With no upcoming binary catalyst for SGX302 and the company's uncertain future, the risk/reward skews negative for this program.

How It Works

SGX302 is a topical gel containing synthetic hypericin, a photosensitizer. When applied to psoriatic skin lesions and then activated by visible light, it produces a localized therapeutic effect. This is called photodynamic therapy: the light-activated compound selectively targets diseased skin cells while sparing healthy tissue. It is the same active ingredient as Soligenix's HyBryte (SGX301), which was studied in cutaneous T-cell lymphoma.

Trial Status

A Phase 2a trial (NCT05442190) evaluating SGX302 topical gel in mild-to-moderate psoriasis enrolled 15 patients across 3 cohorts and completed in November 2025. Positive results were reported: Cohort 2 (Jan 2024) showed 2 of 4 patients achieved target response; Cohort 3 (Dec 2025) showed 3 of 4 patients achieved PASI 75 with an optimized gel formulation, and the drug was well tolerated with no drug-related adverse events. No Phase 2b or Phase 3 trial has been initiated.

The Two-Sided Case

▲ Bull Case5
SGX302 (synthetic hypericin) showed positive Phase 2a signals: in Cohort 3 (Dec 2025), 3 of 4 patients achieved PASI 75 (75% improvement) with an optimized gel formulation, and the drug was well tolerated with no drug-related adverse events.
The active ingredient (hypericin sodium) has orphan drug designations and a known safety profile from the CTCL program; the FDA has already cleared the IND for SGX302.
Soligenix narrowed its Q3 2026 net loss to $1.12M (from $2.53M a year ago) and has cash runway into Q2 2028, giving it time to find a partner or strategic exit.
Analyst consensus shows 6 analysts covering the stock with 2 Strong Buy and 4 Buy ratings (1 Hold), with a mean price target of $1.375, implying significant upside from the current ~$0.335 price, though coverage is stale (last action July 2025).
The photodynamic therapy mechanism is novel for psoriasis and could offer a differentiated topical option if successfully developed.
▼ Bear Case5
Soligenix's lead asset HyBryte (SGX301, same active ingredient) failed its Phase 3 FLASH2 trial in April 2026, with the Data Monitoring Committee recommending the study be halted for futility, casting a shadow over the entire hypericin platform.
SGX302 is only in Phase 2a (12-15 patients total across cohorts), far from registration; a pivotal Phase 2b/3 program would require substantial capital that Soligenix, with only ~$9M cash and no revenue, likely cannot fund alone.
The company is exploring strategic alternatives (partnerships, M&A, licensing) after the FLASH2 failure, creating uncertainty about whether SGX302 will be developed further by Soligenix at all.
The stock trades near its 52-week low at ~$0.335, reflecting deep investor skepticism after the FLASH2 futility halt and the company's uncertain future.
Psoriasis is a highly competitive market with many established topical and systemic treatments (biologics, JAK inhibitors, PDE4 inhibitors), making it difficult for an early-stage photodynamic therapy to differentiate.

Upcoming Catalysts

  • No specific SGX302 catalyst is scheduled. The company's next material event is likely a strategic alternative announcement (partnership, licensing, or M&A) given the FLASH2 failure and the company's public exploration of options.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Soligenix, Inc. PRESS-RELEASE SNGX ·Originating report

Sources · 6

Hover a chip for the title
1 prnewswire.com2 markets.ft.com3 nasdaq.com4 msn.com5 pix11.com6 theglobeandmail.com